Nonetheless, ANGPTL3 inhibitors can lower the concentrations of atherogenic particles independently of LDL receptor function and, hence, may be used in mixed hyperlipidemia and HoFH [13]. This evidence concerns the gene LDLR and Combined hyperlipidemia.